Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06021522 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
A Phase 3 study of Tourette Syndrome, sponsored by Emalex Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06021522 is a Phase 3 study of Tourette Syndrome that is active but no longer recruiting, run by Emalex Biosciences. The registered enrollment target is 150 participants, above the 82-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06021522, a Phase 3 study of Tourette Syndrome, is active but no longer recruiting, sponsored by Emalex Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS).
Conditions Studied
Interventions
- DRUG Ecopipam
Study Locations (20)
Florida
- NW FL Clinical Research Group, LLC - Gulf Breeze
- Research in Miami Inc - Hialeah
- University of Miami Miller School of Medicine - Miami
- Florida International Research Center - Miami
- Medical Research Group of Central Florida - Orange City
- APG Research, LLC - Orlando
- University of South Florida - St. Petersburg
- Pediatric Epilepsy and Neurology Specialists - Tampa
California
- Advanced Research Center - Anaheim
- CenExel CIT-IE - Bellflower
- Cortica Site Network - Glendale
- Cortica Site Network - San Rafael - San Rafael
Illinois
- Lurie Children Hospital of Chicago - Chicago
- Rush University Medical Center - Chicago
Alabama
- Harmonex, Inc. - Dothan
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Yale School of Medicine - New Haven
District of Columbia
- Childrens National Hospital - Washington D.C.
Georgia
- Rare Disease Research, LLC - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06021522
The ClinicalTrials.gov registry entry for NCT06021522 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (83% higher). The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tourette Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Ecopipam is the first listed.
NCT06021522 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06021522 about?
NCT06021522 is a clinical study titled "A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder". The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS)...
What is the current status of trial NCT06021522?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2023-08-16. Estimated completion is 2027-03.
What conditions does trial NCT06021522 study?
This clinical trial studies the following conditions: Tourette Syndrome.
What interventions are being tested in trial NCT06021522?
The interventions under investigation include: Ecopipam (DRUG).
Who is sponsoring clinical trial NCT06021522?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06021522 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
COMPLETED · Phase 3
-
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
RECRUITING
-
Remote Delivery of a Mindfulness-based Intervention for Tics
RECRUITING · NA
-
Sensory Symptoms in Tourette Syndrome
RECRUITING
-
Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
RECRUITING · Phase 2
-
Trajectories of Change in Tourette Syndrome
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.